Midazolam · more major-labeled pairs than Bictegravir
SPL labels Midazolam + Bictegravir as minor; Midazolam 27 / Bictegravir 16 in that band.
Mechanism on file: Clinical studies have shown that these two drugs do not interfere with each other's levels or effectiveness in the body.
FDA SPL severity: Minor
Midazolam + Bictegravir · SPL mechanism field
Clinical studies have shown that these two drugs do not interfere with each other's levels or effectiveness in the body.
Minor band excerpt · Midazolam with Bictegravir
7.6 Drugs without Clinically Significant Interactions with BIKTARVY Based on drug interaction studies conducted with BIKTARVY or the components of BIKTARVY, no clinically significant drug interactions have been observed when BIKTARVY is combined with the following drugs: ethinyl estradiol, ledipasvir/sofosbuvir, midazolam, norgestimate, sertraline, sofosbuvir, sofosbuvir/velpatasvir, and sofosbuvir/velpatasvir/voxilaprevir.
Midazolam · 3 major-labeled pairs (vs Bictegravir's 2)
- Atomoxetine minor
- Atropine minor
- Carbamazepine minor
- Darifenacin minor
Bictegravir · 16 minor + 19 total pairs
- Acyclovir minor
- Carbamazepine minor
- Cidofovir minor
- Estradiol minor
FDA Drug Labels (SPL) via openFDA. Registry display only. Not medical advice.
Read our methodology - how this data is sourced, computed, and verified.